Allworth Financial’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-595
| Closed | -$42.9K | – | 5299 |
|
|
2025
Q4 | $42.9K | Sell |
595
-261
| -30% | -$16.9K | ﹤0.01% | 2299 |
|
|
2025
Q3 | $37.3K | Buy |
856
+159
| +23% | +$6.43K | ﹤0.01% | 2308 |
|
|
2025
Q2 | $19.8K | Buy |
697
+243
| +54% | +$7.24K | ﹤0.01% | 2534 |
|
|
2025
Q1 | $14K | Buy |
454
+19
| +4% | +$592 | ﹤0.01% | 2274 |
|
|
2024
Q4 | $13.1K | Sell |
435
-5
| -1% | -$209 | ﹤0.01% | 2328 |
|
|
2024
Q3 | $20.2K | Hold |
440
| – | – | ﹤0.01% | 1907 |
|
|
2024
Q2 | $19.9K | Buy |
440
+5
| +1% | +$143 | ﹤0.01% | 1892 |
|
|
2024
Q1 | $11.1K | Hold |
435
| – | – | ﹤0.01% | 2063 |
|
|
2023
Q4 | $3.94K | Buy |
435
+395
| +988% | +$2.64K | ﹤0.01% | 2371 |
|
|
2023
Q3 | $256 | Sell |
40
-29
| -42% | -$250 | ﹤0.01% | 3197 |
|
|
2023
Q2 | $766 | Buy |
69
+29
| +73% | +$364 | ﹤0.01% | 2809 |
|
|
2023
Q1 | $614 | Hold |
40
| – | – | ﹤0.01% | 2802 |
|
|
2022
Q4 | $888 | Hold |
40
| – | – | ﹤0.01% | 2512 |
|
|
2022
Q3 | $1K | Hold |
40
| – | – | ﹤0.01% | 2482 |
|
|
2022
Q2 | $1K | Hold |
40
| – | – | ﹤0.01% | 2241 |
|
|
2022
Q1 | $1K | Buy |
+40
| New | +$680 | ﹤0.01% | 2001 |
|
|
2021
Q2 | – | Sell |
-100
| Closed | -$2K | – | 1647 |
|
|
2021
Q1 | $2K | Buy |
+100
| New | +$2.45K | ﹤0.01% | 1328 |
|
Other funds holding RNAM
Allworth Financial's RNAM Position: Q1 2026 in Review
Allworth Financial sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 595 shares — an estimated $42.9K sold.
Allworth Financial first reported a position in RNAM in Q1 2021 and held it in 17 quarters. The position peaked at $42.9K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Allworth Financial reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Allworth Financial sold 595 Avidity Biosciences shares in Q1 2026, an estimated $42.9K.
- Allworth Financial first reported a position in Avidity Biosciences in Q1 2021 and held it in 17 quarters.
- Allworth Financial's Avidity Biosciences position peaked at $42.9K in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.